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Abstract
Background & Aims: Total bilirubin is a predictor of survival in primary biliary chol-
angitis, with the main elevated component being direct bilirubin. The purpose of this 
post hoc analysis was to assess the efficacy and safety of obeticholic acid across 
quartiles of varying baseline levels of direct bilirubin in the phase 3, randomized, 
placebo-controlled Primary Biliary Cholangitis Obeticholic Acid International Study 
of Efficacy.
Methods: This analysis assessed patients on the basis of their baseline direct bilirubin 
level (divided by quartile). Biochemistry and safety outcomes were evaluated within 
each quartile over time.
Results: In the quartile with the highest baseline direct bilirubin (>5.47 µmol/L), there 
was a significant reduction in both direct and total bilirubin at Month 12 compared 
with placebo. Least squares mean (standard error) change from baseline in direct bili-
rubin at Month 12 was 4.17 (1.42) µmol/L for placebo, −3.48 (1.63) µmol/L for obet-
icholic acid 5-10 mg and −3.66 (1.51) µmol/L for obeticholic acid 10 mg (P < .0001, 
obeticholic acid vs placebo); the corresponding values for total bilirubin at Month 
12 were 4.38 (1.55) µmol/L for placebo, −4.53 (1.83) µmol/L for obeticholic acid 
5-10 mg and −5.06 (1.64) µmol/L for obeticholic acid 10 mg (P < .0001, obeticholic 
acid vs placebo).
Conclusions: Obeticholic acid treatment was associated with significant reductions 
in total and direct bilirubin, particularly in patients with high baseline direct bilirubin. 
Because raised direct bilirubin levels, even within the normal range, are predictive of 
survival in primary biliary cholangitis, these results suggest substantial benefits of 
obeticholic acid in at-risk patients.
K E Y W O R D S
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1  | INTRODUC TION
Primary biliary cholangitis (PBC) is a chronic autoimmune liver dis-
ease characterized by inflammation and the progressive destruction 
of bile ducts, cholestasis, eventual cirrhosis and death.1,2 The prog-
nostic significance of several liver chemistries has been evaluated 
and found to be associated with disease progression, including al-
kaline phosphatase (ALP), aspartate aminotransferase (AST) and al-
bumin, with bilirubin being identified as one of the key predictors of 
survival and prognosis in patients with PBC.3-5
Rising total bilirubin levels are a late-stage feature of PBC and are 
associated with negative long-term outcomes in patients with the 
disease.6,7 In an analysis of liver chemistries associated with long-
term outcomes in patients with PBC, a total bilirubin level >1x the 
upper limit of normal (ULN) was a key inverse predictor of trans-
plant-free survival (hazard ratio: 5.06); 86% of patients with a total 
bilirubin level ≤1xULN survived for 10 years after enrolment com-
pared with 41% of patients with levels >1xULN.7 In addition, it has 
been found that total bilirubin values, even within the normal range, 
may have prognostic significance; for example, Trivedi et al showed 
that the optimum cut-off value for total bilirubin in predicting liver 
transplantation or death was 0.70xULN.5 The Global PBC Study 
Group similarly established that rising total bilirubin levels, even 
within the normal range, are predictive of the 5-year risk of liver 
transplantation or death.8 In fact, multiple guidelines, response cri-
teria and risk score calculators used for PBC agree that the stabili-
zation or reduction in total bilirubin levels corresponds to reduced 
risk for disease progression, highlighting the need for PBC treatment 
options that can stabilize or reduce bilirubin levels in patients with 
PBC.4,6,9-17
Most studies and prognostic scores report on only total bilirubin, 
although a key disease-related component of total bilirubin is direct 
or conjugated bilirubin.6-7,18-20 Tahtaci et al evaluated various hae-
matological and biochemical parameters in patients with advanced 
or early-stage PBC and found that, of total and direct bilirubin, only 
direct bilirubin level was significantly higher in patients with late-
stage disease.21 Although fractionation of total bilirubin is not a 
routine clinical laboratory assessment at this time, the American 
College of Gastroenterology's clinical guidelines for the evaluation 
of abnormal liver chemistries recommends that total serum biliru-
bin levels be separated into direct and indirect fractions.22 These 
guidelines state that direct bilirubin elevations, and not indirect ele-
vations, are often present in cholestatic disorders with impairment 
in bile flow.22 In PBC, the levels of bilirubin are elevated mainly by its 
direct fraction.20,23 Taken together, these data and recommenda-
tions suggest that direct bilirubin may be a more sensitive marker for 
PBC severity than total bilirubin. However, given that total bilirubin 
is more commonly evaluated, it has emerged as the dominant prog-
nostic marker in various multivariate analyses assessing treatment 
response and natural history of PBC.
Obeticholic acid (OCA) is a potent and selective farnesoid X re-
ceptor agonist that is indicated for PBC as second-line therapy in 
combination with ursodeoxycholic acid (UDCA) in adults with an 
inadequate response to UDCA or as a monotherapy in those unable 
to tolerate UDCA.24-26 While the approval of OCA is based largely on 
reduction in ALP, beneficial effects in bilirubin have also been noted. 
A phase 2, international, randomized, double-blind, placebo-con-
trolled study of OCA as monotherapy showed a decrease from base-
line in direct bilirubin levels in patients treated for 3 months with 
OCA 10 mg and OCA 50 mg compared with placebo.27 A phase 2, 
randomized, double-blind, placebo-controlled trial of patients with 
PBC who had an inadequate response to UDCA also showed de-
creases in direct bilirubin levels in response to OCA 25 mg and OCA 
50 mg compared with placebo.28
In the pivotal, phase 3 PBC OCA International Study of Efficacy 
(POISE) trial, daily doses of OCA 5-10 mg resulted in a signifi-
cantly greater number of patients achieving the primary endpoint 
(ALP<1.67xULN with a ≥15% reduction in ALP from baseline and a 
total bilirubin level ≤ULN at Month 12) compared with placebo.25 
Compared with a progressive increase in total bilirubin in the pla-
cebo group at Month 12 (2 ± 0.70 μmol/L), patients in the OCA 5 mg 
titrated to 10 mg (OCA 5-10 mg) and OCA 10 mg groups experienced 
a significant reduction in total bilirubin (least squares [LS] mean 
[standard error, SE]: −0.30 [0.70] and −0.90 [0.70] μmol/L respec-
tively).25 OCA treatment therefore prevents increases in bilirubin 
levels in patients with PBC.
Although total bilirubin is predictive of outcomes, direct biliru-
bin is the main elevated component in PBC. As such, this post hoc 
analysis assessed the efficacy and safety of OCA across quartiles of 
varying baseline levels of direct bilirubin in POISE.
2  | MATERIAL S AND METHODS
2.1 | Study design
Detailed methods for POISE, including a CONSORT diagram, were 
previously published (ClinicalTrials.gov, NCT01473524).25 Briefly, 
patients with PBC and an inadequate response to or intolerance 
of UDCA were randomly assigned to placebo, OCA 5-10 mg, or 
OCA 10 mg in the 12-month, double-blind, placebo-controlled, 
phase 3 study.25 The primary composite endpoint in POISE was 
ALP<1.67xULN with a ≥15% reduction in ALP from baseline and a 
total bilirubin level ≤ULN at Month 12.25 The ULN for total bilirubin 
was defined as 19.32 μmol/L for women and 25.48 μmol/L for men, 
and the ULN for direct bilirubin was defined as 3.42 μmol/L for all 
Key points
Treatment with obeticholic acid for 12 months improved 
or stabilized biochemical markers associated with negative 
long-term outcomes in patients with primary biliary chol-
angitis, especially in patients who were considered to be 
at risk of disease progression.
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patients. After the double-blind phase, patients could enrol in the 
open-label extension (OLE) phase, in which all patients were treated 
with OCA.
In this post hoc analysis, patients in the POISE intent-to-treat 
population (N = 216) were pooled across treatment groups and 
equally divided into quartiles by baseline direct bilirubin levels (as 
this is the main elevated component in PBC) to investigate whether 
there was a relationship between baseline direct bilirubin level 
and laboratory measures throughout the course of the study.20,25 
Efficacy and safety analyses were evaluated by direct baseline 
bilirubin quartiles and treatment groups (Table 1). For comparison 
with results from direct bilirubin quartiles, efficacy was also eval-
uated by total bilirubin quartiles. For the assessment of efficacy 
response rate, discontinuations were considered non-responders 
as a conservative form of imputation. Analyses were performed 
for the double-blind phase (initial 12 months); long-term evaluation 
was performed for the OLE of POISE for up to 36 months of OCA 
treatment and is presented in the supplemental material. For the 
OLE analyses, patients were evaluated from the time they initiated 
OCA treatment; for patients randomly assigned to placebo during 
the double-blind phase, the baseline value was the visit immediately 
prior to OCA initiation.
The POISE protocol was approved by local and national ethics 
and regulatory agencies and was conducted in accordance with Good 
Clinical Practice guidelines and the Declaration of Helsinki (Seoul, 
South Korea, October 2008 amendment).27 Written informed con-
sent was obtained from each patient included in the study.
2.2 | Statistical analyses
For the evaluation of the primary endpoint of POISE in each direct 
bilirubin quartile, P-values for comparing treatments were obtained 
using the Cochran-Mantel-Haenszel general association test strati-
fied by the randomization strata factor. P-values for comparing ac-
tive treatments vs placebo for direct and total bilirubin, ALP, AST, 
alanine aminotransferase (ALT) and gamma-glutamyl transferase 
(GGT) levels, as well as for the pruritus visual analog scale (VAS) 
scores, were obtained using an analysis of covariance model with 




Baseline values for most demographic characteristics, UDCA use/
dose and albumin were generally similar across direct bilirubin 
quartiles (Table 2). Of the patients who had direct bilirubin levels 
above the ULN (quartiles 3 and 4), most (83%) had total bilirubin lev-
els within the normal range. The number of male patients and ALP 
and total bilirubin levels increased progressively by direct bilirubin 
quartile, whereas platelet count progressively decreased within in-
creasing direct bilirubin quartiles. Baseline values for AST, ALT and 
GGT did not show clear patterns across quartiles, although the mean 
value of each of these markers was highest in quartile 4.
3.2 | Efficacy
In a comparison between quartiles, direct bilirubin levels remained 
stable in quartiles 1 and 2 across all treatment groups (Figure 1A,B). 
In contrast, both dosages of OCA resulted in a reduction in direct 
bilirubin levels in quartiles 3 and 4 after 12 months of randomized 
treatment, whereas direct bilirubin levels increased in the placebo 
group (Figure 1C,D). Comparison between treatment groups within 
quartiles 3 and 4 showed a statistically significant difference in LS 
mean change from baseline in direct bilirubin levels at Month 12 rela-
tive to placebo (quartile 3: OCA 5-10 mg, −0.26 µmol/L; OCA 10 mg, 
−0.28 µmol/L; placebo, 1.12 µmol/L, both OCA groups, P < .05; 
quartile 4: OCA 5-10 mg, −3.48 µmol/L; OCA 10 mg, −3.66 µmol/L; 
placebo, 4.17 µmol/L, both OCA groups, P < .0001). Long-term as-
sessment throughout 36 months of the OLE also showed the most 
pronounced decrease in direct bilirubin levels in direct bilirubin 
quartiles 3 and 4 (Figure S1).
When total bilirubin was compared across direct bilirubin quar-
tiles, total bilirubin levels remained relatively stable in quartiles 1 and 
2 (Figure 2A,B). In contrast, both dosages of OCA resulted in reduction 
of total bilirubin levels in quartiles 3 and 4 after 12 months of treat-
ment, whereas total bilirubin levels steadily increased from Months 3 
to 12 in the placebo group (Figure 2C,D). The LS mean change in total 
bilirubin levels from baseline at Month 12 was statistically significant 
for both dosage groups of OCA in direct bilirubin quartile 4 relative 
TA B L E  1   Baseline direct bilirubin level for each quartile in POISE
Quartile
Direct Bilirubin Cut-off  
Placebo (n) OCA 5-10 mg (n) OCA 10 mg (n)(µmol/L) (mg/dL)
1 ≤2.05 ≤0.12 18 20 17
2 2.05 to 3.33 0.12 to 0.20 20 17 18
3 3.33 to 5.47 0.20 to 0.32 17 16 19
4 >5.47 >0.32 18 17 19
Note: Bilirubin values in µmol/L were divided by 17.10 to convert to mg/dL.
Abbreviations: OCA, obeticholic acid; PBC, primary biliary cholangitis; POISE, PBC OCA International Study of Efficacy.
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to placebo (OCA 5-10 mg, −4.53 µmol/L; OCA 10 mg, −5.06 µmol/L; 
placebo, 4.38 µmol/L, both OCA groups, P < .0001). There was a 
non-significant reduction in total bilirubin from baseline at Month 12 
in quartile 3 (OCA 5-10 mg, −0.84 µmol/L; OCA 10 mg, −0.48 µmol/L; 
placebo, 0.81 µmol/L). Long-term assessment throughout 36 months 
of the OLE showed sustained reductions in total bilirubin levels for 
direct bilirubin quartiles 3 and 4 (Figure S2).
Additional analyses of patients in the double-blind phase showed 
results similar to those of direct bilirubin when assessed by baseline 
total bilirubin quartiles (Figure S3) or total bilirubin >0.70xULN, a 
cut-off value for bilirubin in predicting liver transplantation or death 
(Figure S4).5,7
Over 12 months of randomized treatment, both dosages of OCA 
resulted in statistically significant reductions in ALP levels across 
each direct bilirubin quartile relative to placebo (Figure 3). The LS 
mean change in ALP from baseline at Month 12 for OCA groups 
relative to placebo was statistically significant for each quartile (all 
quartiles, P < .05 for both OCA groups vs placebo). The magnitude 
of the LS mean change in ALP was generally similar for each OCA 
dose across quartiles. Long-term assessment throughout 36 months 
of the OLE also showed reductions in ALP levels for each direct bili-
rubin quartile (Figure S5).
Compared with patients randomly assigned to placebo, more 
patients randomly assigned to OCA achieved the primary endpoint 
of POISE for each baseline direct bilirubin quartile at Month 12, an 
effect that was significant for OCA 10 mg in quartile 1, both doses 
of OCA in quartiles 2 and 3 and OCA 5-10 mg in quartile 4, and 
this was generally consistent with or greater than the effect in the 
overall cohort (Figure S6). In a long-term assessment of open-label 
treatment, patients in direct bilirubin quartile 4 who received either 
dose of OCA in the double-blind portion of the study had higher 
responder rates at 12, 24 and 36 months than patients who had 
received placebo in the double-blind phase; the other quartiles did 
not show clear differences or patterns across groups (Figure S7A-C).
In a comparison of all baseline direct bilirubin quartiles, ALT, 
GGT and AST levels were also reduced throughout 12 months of 
treatment in both OCA dosage groups vs placebo, and within each 
quartile, this effect was generally significant throughout each time 
point for each marker (Figure S8-10). In addition, 12 months of treat-
ment with OCA reduced the median estimated risk of death or liver 
transplantation at years 5, 10 and 15 per the GLOBE score and UK-
PBC risk score (Figure S11-12). The largest reduction in estimated 
risk was observed in quartile 4, where comparison between OCA 
and placebo achieved statistical significance (P < .01) for both OCA 
dosage groups across all time points.
3.3 | Safety and tolerability
In patients receiving OCA 5-10 mg during the double-blind phase, 
similar incidences of pruritus were observed in each baseline direct 
bilirubin quartile, and they remained generally similar to placebo 
TA B L E  2   Baseline characteristics for direct bilirubin quartiles in POISE
 Quartile 1 (n = 55) Quartile 2 (n = 55) Quartile 3 (n = 52) Quartile 4 (n = 54)
Age, years 57.30 (8.35) 55.40 (10.97) 54.90 (12.03) 55.70 (10.47)
Female, n (%) 54 (98) 52 (95) 47 (90) 43 (80)
Caucasian, n (%) 48 (87) 53 (96) 51 (98) 51 (94)
Duration of PBC, years 7.80 (5.67) 8.80 (6.17) 9.40 (5.58) 8.50 (6.70)
History of PBC-related 
pruritus, n (%)
34 (62) 28 (51) 35 (67) 40 (74)
UDCA use, n (%) 54 (98) 49 (89) 47 (90) 50 (93)
UDCA daily dose, mg/kg 16 (4.61) 15.20 (4.25) 16.70 (6.04) 16 (4.47)
ALP, U/L 293.57 (95.03) 312.11 (114.21) 317.66 (88.88) 369.98 (130.11)
AST, U/L 41.07 (13.16) 45.04 (25) 43.83 (15.30) 72.03 (34.08)
ALT, U/L 45.95 (18.89) 53.28 (33.39) 50.52 (24.33) 81.88 (50.25)
GGT, U/L 223.61 (154.46) 210.71 (117.49) 223.35 (164.63) 441.73 (518.85)
Total bilirubin, μmol/L 6.08 (2.58) 7.79 (1.69) 11.55 (3.41) 19.11 (6.97)
>ULN, n (%) 0 0 2 (4) 16 (30)
Direct bilirubin, μmol/L 1.61 (0.15) 2.73 (0.38) 4.23 (0.61) 11.19 (7.05)
>ULN, n (%) 0 0 50 (96) 54 (100)
Platelets, ×109/L 255.19 (83.76) 247.28 (64.75) 234.84 (87.53) 170.81 (75.65)
Albumin, g/dL 4.29 (0.25) 4.40 (0.24) 4.39 (0.28) 4.20 (0.37)
Note: Data are mean (SD) unless otherwise specified. Quartiles were defined by baseline direct bilirubin levels as follows: quartile 1, ≤2.05 µmol/L; 
quartile 2, 2.05 to 3.33 µmol/L; quartile 3, 3.33 to 5.47 µmol/L; quartile 4, >5.47 µmol/L. The ULN for total bilirubin was as follows: female: 
19.32 μmol/L, male: 25.48 μmol/L; the ULN for direct bilirubin was 3.42 μmol/L for all patients.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; 
POISE, Primary Biliary Cholangitis OCA International Study of Efficacy; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
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in quartiles 1 and 2; however, the incidence of pruritus gener-
ally increased with increasing quartiles in the OCA 10 mg group 
compared with placebo (Table S1). One death unrelated to OCA 
occurred in a patient receiving OCA 5-10 mg; the patient was in 
direct bilirubin quartile 4. During the OLE, the exposure-adjusted 
treatment-emergent adverse event rate for the total OCA group 
generally increased with increasing direct bilirubin quartile for 
overall adverse events, pruritus, serious adverse events and hepa-
tobiliary disorders (Table S2). Hyperbilirubinemia was reported in 
1 patient during the OLE in quartile 4 (data not shown). One death 
occurred in the OLE that was deemed unrelated to OCA.29
In direct bilirubin quartiles 1 and 2, there were no statistical dif-
ferences between treatment groups in pruritus VAS scores; pruritus 
VAS scores were statistically higher in the OCA 10 mg group relative 
to placebo during the first 3-6 months of OCA treatment in direct bil-
irubin quartiles 3 and 4 (Figure S13). The median change from base-
line in pruritus VAS scores for all treatment groups was ≤1 at all time 
points in the double-blind phase in quartiles 1 and 2 (data not shown). 
After 36 months of the OLE, a general increase in pruritus VAS scores 
was observed in direct bilirubin quartiles 3 and 4 (Figure S14).
4  | DISCUSSION
4.1 | Summary of the results and their implications
These results suggest that high baseline direct as well as total biliru-
bin levels identify the risk for worsening of biochemistry in patients 
F I G U R E  1   Changes in direct bilirubin in POISE across 12 months of treatment in each direct bilirubin quartile. (A-B) Quartiles 1 and 2 
represent patients with normal baseline direct bilirubin levels. (C-D) Quartiles 3 and 4 represent patients with baseline direct bilirubin levels 
generally above the ULN (defined as 3.42 μmol/L). Levels of significance: *P < .05, **P < .01, ***P < .0001; P-values were obtained using an 
analysis of covariance model. BL, baseline; DBILI, direct bilirubin; OCA, obeticholic acid; PBC, primary biliary cholangitis; POISE, PBC OCA 
International Study of Efficacy; UDCA, ursodeoxycholic acid; ULN, upper limit of normal













































Quartile 1: BL DBILI ≤2.05 µmol/L
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OCA 5-10 mg ± UDCA, n = 20
Placebo ± UDCA, n = 18
OCA 10 mg ± UDCA, n = 17
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Placebo ± UDCA, n = 20
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 Quartile 4: BL DBILI >5.47 µmol/L
Placebo ± UDCA, n = 18
OCA 5-10 mg ± UDCA, n = 17
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with PBC. Patients receiving placebo with baseline direct bilirubin 
>ULN (quartiles 3 and 4) showed evidence of disease progression 
over the 12-month course of the POISE placebo-controlled study, 
as indicated by rising direct 12-month bilirubin levels. Treatment 
with OCA for 12 months led to significant improvements in direct 
and total bilirubin levels in quartile 4 compared with placebo and 
prevented a rise in ALP, AST, ALT and GGT liver chemistries across 
each baseline direct bilirubin quartile. Significant reductions in the 
estimated risk of negative outcomes per the GLOBE score and UK-
PBC risk score at 5-, 10- and 15-year time points were also observed 
in quartile 4 compared with placebo. The results of this study further 
support the efficacy of OCA, with observed general reductions from 
baseline in each of these parameters regardless of disease severity.
Although total bilirubin is commonly reported as a prognostic 
measure for PBC, data from this study support greater exploration 
of direct bilirubin levels as a measure of disease progression.20 The 
majority of patients in quartiles 3 and 4 had total bilirubin levels 
within the normal range (70% of patients in quartile 4), but their di-
rect bilirubin levels were above the ULN (mean direct bilirubin level 
in quartile 4 was 3.27xULN). These patients showed a decreasing 
trend in platelet count and an increasing trend in ALP level at base-
line, corresponding with increasing total and direct bilirubin levels 
between quartiles. Analyses of quartiles defined by baseline total 
bilirubin levels showed results similar to those of direct bilirubin 
quartiles, and a clear increasing trend was observed in the placebo 
group for direct bilirubin more so than total bilirubin in quartile 3, 
F I G U R E  2   Changes in total bilirubin in POISE across 12 months of treatment in each direct bilirubin quartile. (A-B) Quartiles 1 and 
2 represent patients with normal baseline direct bilirubin levels. (C-D) Quartiles 3 and 4 represent patients with baseline direct bilirubin 
levels generally above the ULN (defined as 3.42 μmol/L). Levels of significance: *P < .05, **P < .01, ***P < .0001; P-values were obtained 
using an analysis of covariance model. BL, baseline; DBILI, direct bilirubin; OCA, obeticholic acid; POISE, Primary Biliary Cholangitis OCA 
International Study of Efficacy; UDCA, ursodeoxycholic acid; ULN, upper limit of normal












































Quartile 1: BL DBILI ≤2.05 µmol/L
Placebo ± UDCA, n = 18
OCA 5–10 mg ± UDCA, n = 20
OCA 10 mg ± UDCA, n = 17
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*
Placebo ± UDCA, n = 20
OCA 5-10 mg ± UDCA, n = 17
OCA 10 mg ± UDCA, n = 18
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Placebo ± UDCA, n = 17
OCA 5-10 mg ± UDCA, n = 16
OCA 10 mg ± UDCA, n = 19


































 Quartile 4: BL DBILI >5.47
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further supporting the possible role of direct bilirubin as a more 
sensitive measure of disease severity. These data combined suggest 
that direct bilirubin measurements should be considered in a clinical 
setting when a patient presents with increasing total bilirubin levels, 
even if the increase in total bilirubin is considered to be within the 
normal range.
Regarding safety, the incidence of treatment-emergent pruri-
tus in patients receiving OCA 5-10 mg was similar to that of pla-
cebo in the lower baseline direct bilirubin quartiles (quartiles 1 and 
2), whereas patients in quartile 4 (with the highest baseline direct 
bilirubin levels) showed an increased incidence of pruritus-related 
discontinuations and the largest increase in pruritus severity relative 
to other quartiles, as assessed by the VAS. This group of patients 
also had the greatest benefit from OCA treatment per biochemical 
evaluations. It should be noted that all patients participating in the 
POISE study had a high risk of disease progression because of an 
inadequate response to or intolerance of UDCA; however, the base-
line disease severity for all patients was generally mild to moderate, 
with few patients having compensated cirrhosis (Child-Pugh A cir-
rhosis).25 Incorrect doses of OCA can pose a risk to patients with 
moderate to severe hepatic impairment (Child-Pugh B/C cirrhosis), 
and it is important to follow recommended dosing and administra-
tion provisions with OCA.24
Evaluation of treatment with OCA in patients with advanced 
PBC continues in two ongoing phase 4 clinical studies. The Study 
of Obeticholic Acid Evaluating Clinical Outcomes in Patients With 
Primary Biliary Cholangitis (COBALT, study 747-302; EudraCT, 
2014-005012-42; ClinicalTrials.gov, NCT02308111) is assessing the 
long-term clinical outcomes of OCA, and study 747-401 (EudraCT, 
2017-001762-13; ClinicalTrials.gov, NCT03633227) is evaluating 
the pharmacokinetics and safety of OCA in patients with PBC and 
moderate to severe hepatic impairment (Child-Pugh B and Child-
Pugh C cirrhosis).30,31
4.2 | Literature context
In patients with PBC, the development of hyperbilirubinemia is as-
sociated with disease progression and impaired bilirubin excretion, 
and the elevation of direct bilirubin may result from obstructed 
F I G U R E  3   Changes in ALP in POISE across 12 months of treatment in each direct bilirubin quartile. (A-B) Quartiles 1 and 2 represent 
patients with normal baseline direct bilirubin levels. (C-D) Quartiles 3 and 4 represent patients with baseline direct bilirubin levels generally 
above the ULN (defined as 3.42 μmol/L). Levels of significance: *P < .05, **P < .01, ***P < .0001; P-values were obtained using an analysis of 
covariance model. ALP, alkaline phosphatase; BL, baseline; DBILI, direct bilirubin; OCA, obeticholic acid; POISE, Primary Biliary Cholangitis 
OCA International Study of Efficacy; UDCA, ursodeoxycholic acid; ULN, upper limit of normal


























































































































Quartile 1: BL DBILI ≤2.05 µmol/L
Placebo ± UDCA, n = 18
OCA 5-10 mg ± UDCA, n = 20
OCA 10 mg ± UDCA, n = 17








 Quartile 2: BL DBILI 2.05 to 3.33 µmol/L
Placebo ± UDCA, n = 20
OCA 5-10 mg ± UDCA, n = 17
OCA 10 mg ± UDCA, n = 18












 Quartile 3: BL DBILI 3.33 to 5.47 µmol/L
Placebo ± UDCA, n = 17
OCA 5-10 mg ± UDCA, n = 16
OCA 10 mg ± UDCA, n = 19










 Quartile 4: BL DBILI >5.47 µmol/L
Placebo ± UDCA, n = 18
OCA 5-10 mg ± UDCA, n = 17
OCA 10 mg ± UDCA, n = 19
(A) (B)
(C) (D)
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bile flow, altered bile ductular integrity or reduced production of 
bile because of defective activity of bile efflux transporters.20,32 
Results from this study support previous data showing that OCA 
may improve total and direct bilirubin levels25; however, the nov-
elty of the analyses performed in this study resides in the in-depth 
evaluation of the effect of OCA across various baseline direct and 
total bilirubin levels. The demonstrated benefits of OCA in the 
analyses shown here are expected to be clinically significant, as 
UDCA-treated patients with PBC who had higher total bilirubin 
levels, even within the normal range, were shown to have an in-
creased risk of liver transplantation or death compared with pa-
tients with lower total bilirubin levels.5,8,33 Our finding that OCA 
reduces both total and direct bilirubin in patients with elevated 
direct bilirubin (quartile 4) supports the potential for OCA to delay 
the occurrence of outcome events, as a bilirubin level of 1.60xULN 
is associated with an accelerated increase in bilirubin and a median 
time of 19 months to an outcome event.34 Even with total biliru-
bin levels well within the normal range, the data presented here 
indicate that direct bilirubin levels may be significantly elevated. 
Although many guidelines and established risk criteria include total 
bilirubin, lower thresholds within the normal range may need to 
be considered for clinical use.4,6,9-17 This is further exemplified by 
the inclusion of total bilirubin as a continuous variable within the 
UK-PBC risk score and Global PBC risk score, suggesting that lower 
total bilirubin levels within any range contribute to a lower risk of 
liver-related/all-cause mortality and liver transplantation.9,16 These 
findings support the use of direct bilirubin measurements as a po-
tentially more distinct marker of disease progression, which may 
shape the standards currently used in the field. However, in clinical 
practice, direct bilirubin levels are typically measured only when 
total bilirubin level is above the ULN, a fact that may attenuate this 
proposal.
4.3 | Limitations of the study
The analyses performed here are post hoc; therefore, this study 
was not specifically powered to detect differences within quar-
tiles. In addition, data presented from the OLE did not include a 
placebo group for comparison to account for natural disease pro-
gression. The study population was not representative of one with 
a high incidence of jaundice; jaundice occurs at total bilirubin levels 
above 51.30 μmol/L, and the highest total bilirubin quartile in POISE 
showed a mean level of 19.12 μmol/L.35
4.4 | Strengths of the study
The analyses presented here support the benefits of OCA for vari-
ous PBC liver chemistries, including total and direct bilirubin levels, 
even in at-risk patient populations. The data used for these analyses 
were collected prospectively as part of an international, randomized, 
placebo-controlled, phase 3 study.
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